OSE Immunotherapeutics Receives a Grant from the French National Research Agency to Validate New Targets Linked to Myeloid Cells And Identify Innovative New Immunotherapies in Oncology

Research program coordinated by the Cancer Research Center of Lyon within the Léon Bérard Cancer Center Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) announc...

More From BioPortfolio on "OSE Immunotherapeutics Receives a Grant from the French National Research Agency to Validate New Targets Linked to Myeloid Cells And Identify Innovative New Immunotherapies in Oncology"